LEWIS, K. D.; PERIS, K.; SEKULIC, A.; STRATIGOS, A. J.; DUNN, L.; EROGLU, Z.; CHANG, A. L. S.; MIGDEN, M. R.; YOO, S.-Y.; MOHAN, K.; COATES, E.; OKOYE, E.; BAURAIN, J.-F.; BECHTER, O.; HAUSCILD, A.; BUTLER, M. O.; HERNANDEZ-AYA, L.; LICITRA, L.; NEVES, R. I.; RUIZ, E. S.; SEEBACH, F.; LOWY, I.; GONCALVES, P.; FURY, M. G. Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s177, 2023. DOI: 10.25251/skin.7.supp.177. Disponível em: https://jofskin.org/index.php/skin/article/view/2002. Acesso em: 22 jul. 2024.